Business
Aadi Bioscience Announces Presentations at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
LOS ANGELES, May 25, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and
About this update from Whitehawk Therapeutics, Inc.
[{"type":"text","content":"LOS ANGELES, May 25, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced poster presentations at the 2023 ASCO Annual Meeting taking place June 2-6, 2023, in Chicago, IL. The abstracts associated with the poster presentations are now available on the ASCO meeting website.\nDetails of the poster presentations are below:\nTitle: \"Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I)\"Date and Time: June 3, 2023, 8:00 AM-11:00 AM CTSession Type/Title: Poster Session - Developmental Therapeutics—Molecularly Targeted Agents and Tumor BiologyPresenter: Gopa Iyer, MD, Memorial Sloan Kettering Cancer CenterAbstract Number: TPS3168\nA trial-in-progress poster detailing the PRECISION I trial will be presented. This study aims to determine the efficacy and safety profile of nab-sirolimus in patients with malignant solid tumors with pathogenic inactivating alterations in TSC1 (Arm A) or TSC2 (Arm B).Available data from the AMPECT exploratory analysis and an expanded access program suggest acceptable efficacy and safety of nab-sirolimus, an mTORi with enhanced antitumor activity, in patients with solid tumors harboring inactivating alterations in TSC1 and/or TSC2.Collaboration with leading next generation sequencing vendors will expedite the identification of patients with qualifying TSC1 or TSC2 alterations; study access will be facilitated through a \"just in time\" approach to trial location activation.Title: \"A phase I study of nanoparticle albumin-bound sirolimus (NAB-S) combined with pazopanib (PAZO) in patients with advanced soft tissue sarcoma (STS)\"Poster Session Display Date and Time: June 3, 2023, 1:15 PM-4:15 PM CTPoster Board Number: 455Poster Discussion Session Date and Time: June 3, 2023, 4:30 PM-6:00 PM CTSession Category: Clinical Research Excluding TrialsSession Title: Poster Discussion Session - SarcomaPresenter: Lee Cranmer, MD, PhD, FACP, Fred Hutch Cancer CenterAbstract Number: 11521\nData from an ongoing Phase 1 investigator-initiated trial evaluating the combination of nab-sirolimus and ...